The Future of Alzheimer's Treatment

L'acannamab, marketed in the United States as l'acambi, makes for a tough treatment regime. It has to be infused through a vein by a nursing professional. Because it can cause potentially life-threatening brain swelling and bleeds, people taking it have to be monitored regularly. A similar antibody, Adju-cannamab was approved by the US Food and Drug Administration in 2021,. but the decision generated controversy because the drug's clinical trial had not shown an ambiguous benefit.